In a retrospective cohort study, RCC patients receiving the mTOR inhibitor everolimus had significantly longer progression-free survival (PFS) if they were regular statin users (median 7.5 vs. 3.2 months). This evidence concerns the gene MTOR and renal cell carcinoma.